Israel - English - Ministry of Health

teva israel ltd - gentamicin as sulfate - solution for injection - gentamicin as sulfate 40 mg / 1 ml - gentamicin - gentamicin is indicated in bacteremia, urinary tract infections, endocarditis, chest infections and other serious systemic infections due to confirmed or expected bacteria that are susceptible to gentamicin, in adults and children, including neonates.

Australia - English - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - gentamicin sulfate, quantity: 4.17 mg/ml (equivalent: gentamicin, qty 3 mg/ml) - injection, intravenous infusion - excipient ingredients: sodium chloride; water for injections; disodium edetate - for the treatment of infections due to one or more susceptible strains of bacteria, including pseudomonas aeruginosa, proteus species (indole positive and indole negative), escherichia coli, klebsiella, enterobacter and serratia species and staphylococcus (including strains resistant to other antibiotics). gentamicin may also be used for the treatment of the following conditions when caused by susceptible organisms: bacteraemia, respiratory tract infections, urinary tract infections, skin and skin structure infections, bone infections, peritonitis, septic abortion and burns complicated by sepsis. aminoglycosides, including gentamicin are generally not indicated in uncomplicated initial episodes of urinary tract infection unless the causative organisms are not susceptible to less toxic antibiotics. in suspected or documented gram-negative sepsis, gentamicin should be considered for initial antimicrobial therapy. therapy may be instituted before obtaining results of susceptibility tests. the decision to continue therapy is based on results of the susceptibility tests, the severity of the infection and risk toxicity. if anaerobic organisms are suspected, antimicrobial therapy in addition to the gentamicin regimen should be considered.

Australia - English - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - gentamicin sulfate, quantity: 4.17 mg/ml (equivalent: gentamicin, qty 3 mg/ml) - injection, intravenous infusion - excipient ingredients: sodium chloride; water for injections; disodium edetate - for the treatment of infections due to one or more susceptible strains of bacteria, including pseudomonas aeruginosa, proteus species (indole positive and indole negative), escherichia coli, klebsiella, enterobacter and serratia species and staphylococcus (including strains resistant to other antibiotics). gentamicin may also be used for the treatment of the following conditions when caused by susceptible organisms: bacteraemia, respiratory tract infections, urinary tract infections, skin and skin structure infections, bone infections, peritonitis, septic abortion and burns complicated by sepsis. aminoglycosides, including gentamicin are generally not indicated in uncomplicated initial episodes of urinary tract infection unless the causative organisms are not susceptible to less toxic antibiotics. in suspected or documented gram-negative sepsis, gentamicin should be considered for initial antimicrobial therapy. therapy may be instituted before obtaining results of susceptibility tests. the decision to continue therapy is based on results of the susceptibility tests, the severity of the infection and risk toxicity. if anaerobic organisms are suspected, antimicrobial therapy in addition to the gentamicin regimen should be considered.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - gentamicin sulfate 10 mg/ml (gentamicin sulfate 16mg/ml (bp) equivalent to 10mg/ml (10,000iu) gentamicin) - solution for infusion - 10 mg/ml - active: gentamicin sulfate 10 mg/ml (gentamicin sulfate 16mg/ml (bp) equivalent to 10mg/ml (10,000iu) gentamicin) excipient: disodium edetate dihydrate sodium hydroxide sulfuric acid water for injection - dbl™ gentamicin injection bp is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: pseudomonas aeruginosa proteus species (indole positive and indole negative) escherichia coli klebsiella - enterobacter - serratia species staphylococcus species (coagulase positive and coagulase negative) dbl™ gentamicin injection bp should be considered for the treatment of the following conditions when caused by susceptible organisms: septicaemia respiratory tract infections infected wounds, bone and soft tissue infections including peritonitis, septic abortion and burns complicated by sepsis urinary tract infections (recurrent, complicated) dbl™ gentamicin injection bp is not routinely indicated in the initial treatment of uncomplicated urinary tract infections unless the organism is resistant to other less toxic antibacterials. dbl™ gentamicin injection bp may be considered as initial therapy in suspected or confirmed gram negative infections and therapy may be instituted before obtained results of susceptibility testing. if anaerobic organisms are suspected, additional antimicrobial therapy should be added to the gentamicin regime.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

b. braun melsungen ag - gentamicin sulfate - eq. gentamicin 3 mg/ml - solution for infusion - 3 mg/ml - gentamicin sulfate - gentamicin

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

b. braun melsungen ag - gentamicin sulfate - eq. gentamicin 3 mg/ml - solution for infusion - 3 mg/ml - gentamicin sulfate - gentamicin

Australia - English - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - gentamicin sulfate, quantity: 1.39 mg/ml (equivalent: gentamicin, qty 1 mg/ml) - injection, intravenous infusion - excipient ingredients: sodium chloride; water for injections - for the treatment of infections due to one or more susceptible strains of bacteria, including pseudomonas aeruginosa, proteus species (indole positive and indole negative), escherichia coli, klebsiella, enterobacter and serratia species and staphylococcus (including strains resistant to other antibiotics). gentamicin may also be used for the treatment of the following conditions when caused by susceptible organisms: bacteraemia, respiratory tract infections, urinary tract infections, skin and skin structure infections, bone infections, peritonitis, septic abortion and burns complicated by sepsis. aminoglycosides, including gentamicin are generally not indicated in uncomplicated initial episodes of urinary tract infection unless the causative organisms are not susceptible to less toxic antibiotics. in suspected or documented gram-negative sepsis, gentamicin should be considered for initial antimicrobial therapy. therapy may be instituted before obtaining results of susceptibility tests. the decision to continue therapy is based on results of the susceptibility tests, the severity of the infection and risk toxicity. if anaerobic organisms are suspected, antimicrobial therapy in addition to the gentamicin regimen should be considered.

Israel - English - Ministry of Health

pharmalogic ltd - gentamicin as sulfate - solution for injection - gentamicin as sulfate 80 mg / 2 ml - gentamicin - gentamicin is indicated in bacteremia, urinary tract infections, endocarditis, chest infections and other serious systemic infections due to confirmed or expected bacteria that are susceptible to gentamicin, in adults and children, including neonates.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - gentamicin sulfate, quantity: 3 mg/ml (equivalent: gentamicin, qty 3 mg/ml) - eye drops, solution - excipient ingredients: polyvinyl alcohol; dibasic sodium phosphate heptahydrate; sodium chloride; disodium edetate; benzalkonium chloride; sodium hydroxide; purified water; hydrochloric acid - gentopic eye drops are indicated in the topical treatment of infections of the external eye and its adnexa caused by susceptible bacteria. such infections include conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcers, blepharitis, blepharoconjunctivits, acute meibomianitis and dacryocystitis.

United States - English - NLM (National Library of Medicine)

general injectables & vaccines, inc - gentamicin sulfate (unii: 8x7386qrlv) (gentamicin - unii:t6z9v48ikg) - gentamicin 40 mg in 1 ml - to reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. gentamicin sulfate injection, usp is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: pseudomonas aeruginosa, proteus species (indole-positive and indole-negative), escherichia coli, klebsiella-enterobacter-serratia species, citrobacter species, and staphylococcus species (coagulase-positive and coagulase-negative). clinical studies have shown gentamicin sulfate injection, usp to be effective in bacterial neonatal sepsis; bacter